Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease

1 October, 2014

IMPORTANCE: Several studies suggest that the apolipoprotein E (APOE) epsilon4 allele modulates cerebrospinal fluid (CSF) levels of beta-amyloid 42 (Abeta42). Whether this effect is secondary to the association of the APOE epsilon4 allele with cortical Abeta deposition or whether APOE epsilon4 directly influences CSF levels of Abeta42 independently of Abeta pathology remains unknown. OBJECTIVE: To

Read the article

Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

7 May, 2014

INTRODUCTION: The objective was to study whether alpha-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls. METHODS: In total, 247 CSF samples were assessed in this study, including 71 patients with DLB,

Read the article

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies

21 January, 2014

The proteoglycan NG2 plays a major role in proliferation, migration, and differentiation of pericytes and NG2 cells in the brain. We have previously reported decreased soluble NG2 (sNG2) levels in cerebrospinal fluid (CSF) from patients with Alzheimer’s disease (AD) and a relationship between sNG2 and AD biomarkers in these patients. To further investigate whether alterations

Read the article

Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment

31 July, 2013

Neuroinflammation may be involved in the pathophysiology of Parkinson’s disease (PD) and specifically in non-motor symptoms such as depression, fatigue and cognitive impairment. The aim of this study was to measure inflammatory markers in cerebrospinal fluid (CSF) samples from PD patients and a reference group, and to investigate correlations between non-motor symptoms and inflammation. We

Read the article

Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography

13 June, 2013

PURPOSE: The aim of the study was to determine the usefulness of diffusion tensor tractography (DTT) in parkinsonian disorders using a recently developed method for normalization of diffusion data and tract size along white matter tracts. Furthermore, the use of DTT in selected white matter tracts for differential diagnosis was assessed. METHODS: We quantified global

Read the article

Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy

8 January, 2013

Neurosin is a protease that in vitro degrades alpha-synuclein, the main constituent of Lewy bodies found in brains of patients with synucleinopathy including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Several studies have reported reduced cerebrospinal fluid (CSF) levels of alpha-synuclein in synucleinopathy patients and recent data also proposes a significant role of

Read the article

Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases

7 December, 2012

Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) reflect brain biochemistry. Using combined immunoprecipitation and mass spectrometry, we have shown that amyloid beta 1-15 (Abeta1-15) is produced by concerted beta- and alpha-secretase cleavage of amyloid precursor protein (APP) and that the relative levels of Abeta1-16 in AD compared to controls are increased. Furthermore, drug-induced gamma-secretase

Read the article